Bradanicline
 |
|
| Clinical data | |
|---|---|
| Identifiers | |
|
|
| Synonyms | TC-5619 |
| CAS Number | 639489-84-2 |
| PubChem (CID) | 16727410 |
| UNII | UM3821998K  Y |
| ChEMBL | CHEMBL1258006 |
| Chemical and physical data | |
| Formula | C22H23N3O2 |
| Molar mass | 361.437 g/mol |
| 3D model (Jmol) | Interactive image |
|
|
| (verify) | |
Bradanicline (INN,[1] code name TC-5619) is a drug which was being developed by Targacept that acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors. It showed cognitive enhancing effects in animal studies, and was being developed through a collaboration between Targacept and AstraZeneca as a potential treatment for schizophrenia and attention deficit disorder. [2] Phase I clinical trials were completed successfully, and it was in phase II trials.[3]
In May 2011, AstraZeneca declined to exercise its right to license the compound.[4] In September 2012, Targacept ended its development of badanicline for the purpose of treating ADHD in adults.[5] It was being studied for cognitive and memory enhancement.[6]
Bradanicline was discontinued for Alzheimer's disease and cognitive impairment in schizophrenia in late 2013.[7] It was also discontinued for ADHD, and no longer seems to be being developed.[7]
References[edit]
- ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 73" (PDF). World Health Organization. pp. 68–9. Retrieved 3 January 2017.
- ^ TC-5619 Cognitive Dysfunction in Schizophrenia Archived August 20, 2008, at the Wayback Machine.
- ^ Rethinking Schizophrenia
- ^ Targacept retains full development rights for TC-5619
- ^ Targacept ends development of ADHD drug
- ^ "Statement on a Nonproprietary Name Adopted by the USAN Council" (PDF). November 27, 2013.
- ^ a b http://adisinsight.springer.com/drugs/800026693
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
